Thyro-chord

Homeopathic Liquid


Energetix Corporation
Human Otc Drug
NDC 64578-0076
Thyro-chord also known as Homeopathic Liquid is a human otc drug labeled by 'Energetix Corporation'. National Drug Code (NDC) number for Thyro-chord is 64578-0076. This drug is available in dosage form of Liquid. The names of the active, medicinal ingredients in Thyro-chord drug includes .alpha.-ketoglutaric Acid - 12 [hp_X]/59.1mL Acetic Acid - 15 [hp_X]/59.1mL Ammonium Chloride - 15 [hp_X]/59.1mL Asparagus - 12 [hp_X]/59.1mL Chelidonium Majus - 4 [hp_X]/59.1mL Coenzyme A - 12 [hp_X]/59.1mL Copper - 15 [hp_X]/59.1mL Echinacea Angustifolia - 4 [hp_X]/59.1mL Ferrous Iodide - 12 [hp_X]/59.1mL Fucus Vesiculosus - 6 [hp_X]/59.1mL and more. The currest status of Thyro-chord drug is Active.

Drug Information:

Drug NDC: 64578-0076
The labeler code and product code segments of the National Drug Code number, separated by a hyphen. Asterisks are no longer used or included within the product code segment to indicate certain configurations of the NDC.
Proprietary Name: Thyro-chord
Also known as the trade name. It is the name of the product chosen by the labeler.
Product Type: Human Otc Drug
Indicates the type of product, such as Human Prescription Drug or Human OTC Drug. This data element corresponds to the “Document Type” of the SPL submission for the listing.
Non Proprietary Name: Homeopathic Liquid
Also known as the generic name, this is usually the active ingredient(s) of the product.
Labeler Name: Energetix Corporation
Name of Company corresponding to the labeler code segment of the ProductNDC.
Dosage Form: Liquid
The translation of the DosageForm Code submitted by the firm. There is no standard, but values may include terms like `tablet` or `solution for injection`.The complete list of codes and translations can be found www.fda.gov/edrls under Structured Product Labeling Resources.
Status: Active
FDA does not review and approve unfinished products. Therefore, all products in this file are considered unapproved.
Substance Name:.ALPHA.-KETOGLUTARIC ACID - 12 [hp_X]/59.1mL
ACETIC ACID - 15 [hp_X]/59.1mL
AMMONIUM CHLORIDE - 15 [hp_X]/59.1mL
ASPARAGUS - 12 [hp_X]/59.1mL
CHELIDONIUM MAJUS - 4 [hp_X]/59.1mL
COENZYME A - 12 [hp_X]/59.1mL
COPPER - 15 [hp_X]/59.1mL
ECHINACEA ANGUSTIFOLIA - 4 [hp_X]/59.1mL
FERROUS IODIDE - 12 [hp_X]/59.1mL
FUCUS VESICULOSUS - 6 [hp_X]/59.1mL
FUMARIC ACID - 12 [hp_X]/59.1mL
GENTIANA LUTEA ROOT - 4 [hp_X]/59.1mL
GLYCYRRHIZA GLABRA - 4 [hp_X]/59.1mL
GOLD - 15 [hp_X]/59.1mL
IODINE - 8 [hp_X]/59.1mL
MERCURIUS SOLUBILIS - 15 [hp_X]/59.1mL
NADIDE - 12 [hp_X]/59.1mL
OYSTER SHELL CALCIUM CARBONATE, CRUDE - 12 [hp_X]/59.1mL
PALLADIUM - 15 [hp_X]/59.1mL
PERSICARIA PUNCTATA - 12 [hp_X]/59.1mL
PHOSPHORIC ACID - 12 [hp_X]/59.1mL
POTASSIUM IODIDE - 12 [hp_X]/59.1mL
PULSATILLA VULGARIS - 12 [hp_X]/59.1mL
RANCID BEEF - 12 [hp_X]/59.1mL
SAGE - 8 [hp_X]/59.1mL
SILICON DIOXIDE - 12 [hp_X]/59.1mL
SILVER - 15 [hp_X]/59.1mL
SODIUM DIETHYL OXALACETATE - 12 [hp_X]/59.1mL
SODIUM PYRUVATE - 12 [hp_X]/59.1mL
SUCCINIC ACID - 12 [hp_X]/59.1mL
THYROID, UNSPECIFIED - 9 [hp_X]/59.1mL
TIN - 15 [hp_X]/59.1mL
VANADIUM - 15 [hp_X]/59.1mL
ZINC OXIDE - 15 [hp_X]/59.1mL
This is the active ingredient list. Each ingredient name is the preferred term of the UNII code submitted.
Route Details:ORAL
The translation of the Route Code submitted by the firm, indicating route of administration. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.

Marketing Information:

An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
Marketing Category: UNAPPROVED HOMEOPATHIC
Product types are broken down into several potential Marketing Categories, such as New Drug Application (NDA), Abbreviated New Drug Application (ANDA), BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.
Marketing Start Date: 08 Sep, 2017
This is the date that the labeler indicates was the start of its marketing of the drug product.
Marketing End Date: 25 Dec, 2025
This is the date the product will no longer be available on the market. If a product is no longer being manufactured, in most cases, the FDA recommends firms use the expiration date of the last lot produced as the EndMarketingDate, to reflect the potential for drug product to remain available after manufacturing has ceased. Products that are the subject of ongoing manufacturing will not ordinarily have any EndMarketingDate. Products with a value in the EndMarketingDate will be removed from the NDC Directory when the EndMarketingDate is reached.
Listing Expiration Date: 31 Dec, 2023
This is the date when the listing record will expire if not updated or certified by the firm.

OpenFDA Information:

An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
Manufacturer Name:Energetix Corporation
Name of manufacturer or company that makes this drug product, corresponding to the labeler code segment of the NDC.
Original Packager:Yes
Whether or not the drug has been repackaged for distribution.
NUI:N0000185371
N0000175629
N0000184306
M0000728
M0006342
M0022575
M0005152
N0000175831
N0000008595
N0000008924
N0000175830
N0000185375
M0016962
N0000185508
Unique identifier applied to a drug concept within the National Drug File Reference Terminology (NDF-RT).
UNII:8ID597Z82X
Q40Q9N063P
01Q9PC255D
Z1EJP3037Z
7E889U5RNN
SAA04E81UX
789U1901C5
VB06AV5US8
F5452U54PN
535G2ABX9M
88XHZ13131
S72O3284MS
2788Z9758H
79Y1949PYO
9679TC07X4
324Y4038G2
0U46U6E8UK
2E32821G6I
5TWQ1V240M
D32E7AXD4R
E4GA8884NN
1C4QK22F9J
I76KB35JEV
29SUH5R3HU
065C5D077J
ETJ7Z6XBU4
3M4G523W1G
6CA025Y4FG
POD38AIF08
AB6MNQ6J6L
0B4FDL9I6P
387GMG9FH5
00J9J9XKDE
SOI2LOH54Z
Unique Ingredient Identifier, which is a non-proprietary, free, unique, unambiguous, non-semantic, alphanumeric identifier based on a substance’s molecular structure and/or descriptive information.
Pharmacologic Class EPC:Non-Standardized Food Allergenic Extract [EPC]
Copper-containing Intrauterine Device [EPC]
Non-Standardized Plant Allergenic Extract [EPC]
Standardized Chemical Allergen [EPC]
Established pharmacologic class associated with an approved indication of an active moiety (generic drug) that the FDA has determined to be scientifically valid and clinically meaningful. Takes the form of the pharmacologic class, followed by `[EPC]` (such as `Thiazide Diuretic [EPC]` or `Tumor Necrosis Factor Blocker [EPC]`.
Pharmacologic Class PE:Increased Histamine Release [PE]
Cell-mediated Immunity [PE]
Decreased Embryonic Implantation [PE]
Decreased Sperm Motility [PE]
Inhibit Ovum Fertilization [PE]
Physiologic effect or pharmacodynamic effect—tissue, organ, or organ system level functional activity—of the drug’s established pharmacologic class. Takes the form of the effect, followed by `[PE]` (such as `Increased Diuresis [PE]` or `Decreased Cytokine Activity [PE]`.
Pharmacologic Class CS:Allergens [CS]
Dietary Proteins [CS]
Vegetable Proteins [CS]
Copper [CS]
Plant Proteins [CS]
Chemical structure classification of the drug product’s pharmacologic class. Takes the form of the classification, followed by `[Chemical/Ingredient]` (such as `Thiazides [Chemical/Ingredient]` or `Antibodies, Monoclonal [Chemical/Ingredient].
Pharmacologic Class:Allergens [CS]
Cell-mediated Immunity [PE]
Copper Absorption Inhibitor [EPC]
Copper [CS]
Copper-containing Intrauterine Device [EPC]
Decreased Copper Ion Absorption [PE]
Decreased Embryonic Implantation [PE]
Decreased Sperm Motility [PE]
Dietary Proteins [CS]
Increased Histamine Release [PE]
Inhibit Ovum Fertilization [PE]
Non-Standardized Food Allergenic Extract [EPC]
Non-Standardized Plant Allergenic Extract [EPC]
Plant Proteins [CS]
Standardized Chemical Allergen [EPC]
Vegetable Proteins [CS]
These are the reported pharmacological class categories corresponding to the SubstanceNames listed above.

Packaging Information:

Package NDCDescriptionMarketing Start DateMarketing End DateSample Available
64578-0076-159.1 mL in 1 BOTTLE, DROPPER (64578-0076-1)08 Sep, 2017N/ANo
Package NDC number, known as the NDC, identifies the labeler, product, and trade package size. The first segment, the labeler code, is assigned by the FDA. Description tells the size and type of packaging in sentence form. Multilevel packages will have the descriptions concatenated together.

Purpose:

Purpose temporary relief of cold extremities, exhaustion, weakness.

Product Elements:

Thyro-chord homeopathic liquid acetic acid acetic acid .alpha.-ketoglutaric acid .alpha.-ketoglutaric acid ammonium chloride ammonium cation silver silver asparagus asparagus gold gold oyster shell calcium carbonate, crude oyster shell calcium carbonate, crude chelidonium majus chelidonium majus coenzyme a coenzyme a copper copper echinacea angustifolia echinacea angustifolia ferrous iodide ferrous iodide fucus vesiculosus fucus vesiculosus fumaric acid fumaric acid gentiana lutea root gentiana lutea root glycyrrhiza glabra glycyrrhiza glabra iodine iodine potassium iodide iodide ion mercurius solubilis mercurius solubilis nadide nadide sodium diethyl oxalacetate diethyl oxalacetate sodium pyruvate pyruvic acid palladium palladium phosphoric acid phosphoric acid persicaria punctata persicaria punctata pulsatilla vulgaris pulsatilla vulgaris rancid beef rancid beef sage sage silicon dioxide silicon dioxide tin tin succinic acid succinic acid thyroid, unspecified thyroid, unspecified vanadium vanadium zinc oxide zinc cation water glycerin alcohol

Indications and Usage:

Uses temporary relief of cold extremities, exhaustion, weakness.

Warnings:

Warnings in case of overdose, get medical help or contact a poison control center right away. if pregnant or breast-feeding , ask a healthcare professional before use. ​keep out of reach of children.

Dosage and Administration:

Directions take 30 drops orally twice daily or as directed by a healthcare professional. consult a physician for use in children under 12 years of age or if symptoms worsen or persist.

Package Label Principal Display Panel:

Energetix thyro-chord homeopathic remedy cold extremities, exhaustion, weakness 2 fl oz (59.1 ml) / 15% ethyl alcohol 2 oz bottle label purpose temporary relief of cold extremities, exhaustion, weakness.

Further Questions:

Distributed by energetix corp. dahlonega, ga 30533 questions? 800.990.7085 www.goenergetix.com


Comments/ Reviews:

* Data of this site is collected from www.fda.gov. This page is for informational purposes only. Always consult your physician with any questions you may have regarding a medical condition.